Respiratory News and Research

RSS

$FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL$

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

7 Jul 2014

WHO presents new framework to eliminate TB in 33 countries

The World Health Organization today, together with the European Respiratory Society, presented a new framework to eliminate tuberculosis (TB) in countries with low levels of the disease. Today there are 33 countries and territories where there are fewer than 100 TB cases per million population.

3 Jul 2014

FDA grants Fast Track designation to Akashi Therapeutics' HT-100 for treatment of DMD

Akashi Therapeutics, Inc., announced today that the U.S. Food and Drug Administration has granted Fast Track designation to the company's most advanced product candidate, HT-100 (delayed-release halofuginone), an orally available, small molecule drug candidate intended to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with DMD.

3 Jul 2014

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.

3 Jul 2014

Study finds deployment-related respiratory symptoms in veterans returning from Iraq, Afghanistan

In a new study of the causes underlying respiratory symptoms in military personnel returning from duty in Iraq and Afghanistan, a large percentage of veterans had non-specific symptoms that did not lead to a specific clinical diagnosis.

3 Jul 2014

Forest Laboratories completes acquisition of Furiex Pharmaceuticals

Actavis plc today announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc. in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

2 Jul 2014

MedImmune initiates MEDI8897 phase I clinical studies for treatment of RSV infections

AIMM Therapeutics, a leading human therapeutic antibody company, today announced that its partner MedImmune, LLC, the global biologics unit of AstraZeneca, has initiated phase I clinical studies with MEDI8897, a best-in-class antibody for the treatment of respiratory syncytial virus (RSV) infections in young, at risk children.

2 Jul 2014

Exome sequencing improves diagnosis of mitochondrial disease

Use of exome sequencing improved the ability to identify the underlying gene mutations in patients with biochemically defined defects affecting multiple mitochondrial respiratory chain complexes (enzymes that are involved in basic energy production), according to a study in the July 2 issue of JAMA.

2 Jul 2014

Elderly mRCC patients should not be excluded from targeted therapy option

Advanced age is not a reason to preclude patients from receiving vascular endothelial growth factor-targeted therapy for metastatic renal cell carcinoma, show study findings from a mixed-age patient population.

1 Jul 2014

LINX Reflux Management System safe for patients suffering from GERD, shows new data

Torax Medical today announced the release of new data from two leading U.S. medical centers that further establishes the LINX Reflux Management System as a safe and effective procedure for patients suffering from gastroesophageal reflux disease (GERD).

1 Jul 2014

Heavy drinkers at greater risk of developing pneumonia and ARDS

Heavy drinking damages the body in many ways. In addition to liver failure, alcoholics are at a much greater risk of developing pneumonia and life threatening acute respiratory distress syndrome (ARDS), for which there is no treatment.

1 Jul 2014

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT) has approved LemtradaTM (alemtuzumab) for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.

30 Jun 2014

Amyotrophic lateral sclerosis in veterans: an interview with Milan Michael Karol, The Robert Packard Center for ALS Research at Johns Hopkins

ALS stands for Amyotrophic Lateral Sclerosis, better known as “Lou Gehrig’s Disease”. It is a progressive neurodegenerative disease characterized by the death of motor neurons in the brain and spinal cord.

30 Jun 2014

New research project aims to tackle antibiotic resistance with inhalable nanotherapeutics

A new research project (PneumoNP) is aimed at tackling antibiotic resistance in respiratory tract infections via the use of inhalable nanotherapeutic compounds. Funded under the FP7 programme by the European Commission, the 4-year long PneumoNP project brings together top research institutes, universities, clinicians and enterprises from 6 EU member states.

28 Jun 2014

Study explores metabolic activities of unique microbes for cleaning environmental contaminants

Chlorinated chemicals perform a host of societally useful functions, but they also have a dark side. Once their use life has ended, such agents often become environmental contaminants, sometimes resistant to bioremediation.

28 Jun 2014

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending the approval of KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

28 Jun 2014

ALS is aggravated by over-activity of HDAC6 enzyme, shows study

Scientists at VIB and KU Leuven have demonstrated in fruit-flies that over-activity of the enzyme HDAC6 in the nerve ends exacerbates the symptoms of the neurodegenerative condition Amyotrophic Lateral Sclerosis (ALS / Lou Gehrig's Disease). Inhibition of this enzyme could offer a protective effect against ALS.

27 Jun 2014

Respiratory News and Research

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

WHO presents new framework to eliminate TB in 33 countries

FDA grants Fast Track designation to Akashi Therapeutics' HT-100 for treatment of DMD

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

Study finds deployment-related respiratory symptoms in veterans returning from Iraq, Afghanistan

Forest Laboratories completes acquisition of Furiex Pharmaceuticals

MedImmune initiates MEDI8897 phase I clinical studies for treatment of RSV infections

Exome sequencing improves diagnosis of mitochondrial disease

Elderly mRCC patients should not be excluded from targeted therapy option

LINX Reflux Management System safe for patients suffering from GERD, shows new data

Heavy drinkers at greater risk of developing pneumonia and ARDS

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Amyotrophic lateral sclerosis in veterans: an interview with Milan Michael Karol, The Robert Packard Center for ALS Research at Johns Hopkins

New research project aims to tackle antibiotic resistance with inhalable nanotherapeutics

Study explores metabolic activities of unique microbes for cleaning environmental contaminants

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

ALS is aggravated by over-activity of HDAC6 enzyme, shows study

New article explores how specific types of interferons control RNA virus infection

Motivational interviewing reduces secondhand smoke exposure among children living in households

Research: TB infection among people taking corticosteroid pills may be underestimated

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News